ProMIS Neurosciences Inc PMN

Healthcare Biotechnology

ProMIS Neurosciences Inc. is a clinical-stage biotechnology company. It is focused on generating and developing antibody therapeutics selectively targeting toxic misfolded proteins in neurodegenerative diseases such as Alzheimer’s disease (AD), amyotrophic lateral sclerosis (ALS) and multiple system atrophy (MSA). Its proprietary target discovery engine applies a thermodynamic, computational discovery platform-ProMIS and Collective Coordinates-to predict novel targets known as Disease Specific Epitopes on the molecular surface of misfolded proteins. Using this approach, the Company is developing novel antibody therapeutics for AD, ALS and MSA. Its product candidates are PMN310, PMN267, and PMN442. The PMN310 is a monoclonal antibody designed to treat AD by selectively targeting toxic, misfolded oligomers of amyloid-beta. PMN267 product candidate targeting ALS. PMN442 is a drug candidate being developed for MSA designed to selectively target and protect against pathogenic a-syn species.

NDAQ:PMN - Post by User

ProMIS Neurosciences Inc > What's bringing us down ?

<< Previous

Bullboard Posts

Next >>

Comment by G1945Von Jul 21, 2021 5:46am

172 Views

Post# 33580154

RE:RE:RE:RE:What's bringing us down ?

M101: Not sure I understand your point of view, but the Amyloid hypothesis is still alive and aducanumab has thus far maintained that view. Not sure why you are saying that the hypothesis somehow belongs to Goldstein. The hypothesis continues and PMN310 has a good opportunity to improve it. PMN310 selectivity is yet to be proven. Only clinicals can do that.

Perhaps we're saying the same thing in different ways.

jmo
G1945V

<< Previous

Bullboard Posts

Next >>

The Market Online’s Weekly Gold Report – Nov. 6, 2024